Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

This publication has 14 references indexed in Scilit:

• BLOCKING OF TRANSMISSION TO MOSQUITOES BY ANTIBODY TO PLASMODIUM VIVAX MALARIA VACCINE CANDIDATES PVS25 AND PVS28 DESPITE ANTIGENIC POLYMORPHISM IN FIELD ISOLATES
  The American Journal of Tropical Medicine and Hygiene, 2003
• Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials
  Vaccine, 2002
• Large-Scale Purification and Characterization of Malaria Vaccine Candidate Antigen Pvs25H for Use in Clinical Trials
  Protein Expression and Purification, 2002
• Progress and challenges for malaria vaccines
  Nature, 2002
• Interaction between Host Complement and Mosquito-Midgut-StagePlasmodium berghei
  Infection and Immunity, 2001
• Current developments in malaria transmission-blocking vaccines
  Expert Opinion on Biological Therapy, 2001
• Transmission blocking malaria vaccines
  Vaccine, 2001
• The neglected burden of Plasmodium vivax malaria
  The American Journal of Tropical Medicine and Hygiene, 2001
• Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect Mosquitoes
  Infection and Immunity, 2000
• Biosynthesis of the 25-kDa protein in the macrogametes/zygotes of Plasmodium falciparum
  Experimental Parasitology, 1990